Scilex Holding Company — Form 8-K Summary
Business Context and Reporting Period
Scilex Holding Company filed a Form 8-K on September 8, 2023, reporting an event occurring on September 1, 2023. The filing concerns litigation involving Sorrento Therapeutics, Scilex’s controlling stockholder, and Scilex Pharmaceuticals Inc., a wholly owned subsidiary.
Key Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating financial metrics.
Material Developments
- The Delaware Court of Chancery issued a memorandum opinion addressing liability in litigation originally filed in March 2021 against Anthony Mack, former President of Scilex Pharma, and Virpax Pharmaceuticals, Inc., a company founded by Mr. Mack.
- The court found that Mr. Mack breached his restrictive covenants agreement with Sorrento by developing Epoladerm, breached his fiduciary duty of loyalty to Scilex Pharma, and misappropriated certain Scilex Pharma trade secrets.
- The court found Virpax liable for tortious interference with the restrictive covenants agreement, aiding and abetting Mr. Mack’s breach of fiduciary duty, and misappropriating certain Scilex Pharma trade secrets.
- Sorrento and Scilex Pharma waived claims concerning breach of Mr. Mack’s employment contract and tortious interference with prospective economic advantage.
Remedies, Outlook, and Risks
The court did not determine an appropriate remedy. The parties must participate in further proceedings to determine the remedy implementing the liability findings.
Sorrento and Scilex Pharma are seeking equitable and monetary relief, potentially including an injunction, extension of the restrictive covenants agreement, damages, a constructive trust, and a reasonable royalty on revenues that may eventually be generated by the products at issue. The filing does not state whether any remedy will be granted, the amount of any potential damages, or the timing of further proceedings.
Important Facts to Verify
- The final remedy and any monetary damages or royalty ultimately awarded.
- Whether an injunction or extension of the restrictive covenants agreement is imposed.
- Any appeals or subsequent developments in the Delaware litigation.
- The potential effect of the litigation and any resulting remedy on Scilex’s products, operations, and financial statements.